📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Lincoln Pharma Q3 Net Profit Surges 37.7% YoY to ₹28.6 Crore; Revenue Up 13.5%
Lincoln Pharmaceuticals reported a strong performance for the quarter ended December 31, 2025, with consolidated net profit rising 37.7% YoY to ₹28.60 crore. Revenue from operations grew by 13.5% YoY to ₹166.32 crore, supported by steady growth in its core pharmaceutical business. The company's profitability improved significantly on a sequential basis, with net profit jumping 43.1% compared to the previous quarter. For the nine-month period, the company maintained a healthy trajectory with a net profit of ₹76.26 crore on revenues of ₹483.75 crore.
Key Highlights
Consolidated Revenue from Operations grew 13.5% YoY to ₹166.32 crore in Q3 FY26
Net Profit for the quarter stood at ₹28.60 crore, up from ₹20.77 crore in the same period last year
Earnings Per Share (EPS) increased to ₹14.28 from ₹10.37 in Q3 FY25
Profit Before Tax (PBT) rose to ₹34.72 crore, reflecting improved operational efficiency
Nine-month (9M FY26) revenue reached ₹483.75 crore with a net profit of ₹76.26 crore
💼 Action for Investors
The strong YoY and QoQ growth in profitability suggests robust operational performance. Investors should monitor the sustainability of these margins and the company's expansion in the pharmaceutical segment.
CRISIL Reaffirms Lincoln Pharmaceuticals' Credit Rating at 'CRISIL A/Stable' and 'CRISIL A1'
CRISIL has reaffirmed Lincoln Pharmaceuticals' long-term rating at 'CRISIL A/Stable' and short-term rating at 'CRISIL A1' for its Rs 102 crore bank facilities. The company maintains a robust financial profile with zero debt and a healthy net worth of Rs 671 crore as of March 31, 2025. Revenue grew by 14% YoY to Rs 623 crore in FY25, supported by a strong export presence contributing 60-65% of total sales. While the liquidity position is strong with Rs 173.1 crore in liquid investments, investors should monitor the increase in loans to affiliates, which rose to Rs 141 crore.
Key Highlights
CRISIL reaffirmed long-term rating at 'CRISIL A/Stable' and short-term rating at 'CRISIL A1' for Rs 102 crore facilities.
Company reported zero debt as of March 31, 2025, with a high interest coverage ratio of 91.01 times.
Revenue grew 14% year-on-year to Rs 623.23 crore in FY25, driven by 1,700 registered products.
Liquid investments in shares, debentures, and mutual funds stood at Rs 173.1 crore.
Loans and advances to affiliates increased to Rs 141 crore from Rs 104 crore in the previous year.
💼 Action for Investors
The reaffirmation of ratings and zero-debt status highlights the company's strong solvency and financial health. Investors should remain positive but monitor the rising loans to affiliates and the working capital cycle.